28 related articles for article (PubMed ID: 38748262)
1. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
Ulase D; Behrens HM; Röcken C
Virchows Arch; 2024 May; ():. PubMed ID: 38748262
[TBL] [Abstract][Full Text] [Related]
2. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
[TBL] [Abstract][Full Text] [Related]
3. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
[TBL] [Abstract][Full Text] [Related]
4. The adipocyte microenvironment and cancer.
Mukherjee A; Bilecz AJ; Lengyel E
Cancer Metastasis Rev; 2022 Sep; 41(3):575-587. PubMed ID: 35941408
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Implications of FABP4 in Cancer: An Emerging Target to Tackle Cancer.
Sun N; Zhao X
Front Pharmacol; 2022; 13():948610. PubMed ID: 35899119
[TBL] [Abstract][Full Text] [Related]
6. CD36: an emerging therapeutic target for cancer and its molecular mechanisms.
Ruan C; Meng Y; Song H
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1551-1558. PubMed ID: 35224665
[TBL] [Abstract][Full Text] [Related]
7. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
[TBL] [Abstract][Full Text] [Related]
8. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
[TBL] [Abstract][Full Text] [Related]
9. Interpretable survival prediction for colorectal cancer using deep learning.
Wulczyn E; Steiner DF; Moran M; Plass M; Reihs R; Tan F; Flament-Auvigne I; Brown T; Regitnig P; Chen PC; Hegde N; Sadhwani A; MacDonald R; Ayalew B; Corrado GS; Peng LH; Tse D; Müller H; Xu Z; Liu Y; Stumpe MC; Zatloukal K; Mermel CH
NPJ Digit Med; 2021 Apr; 4(1):71. PubMed ID: 33875798
[TBL] [Abstract][Full Text] [Related]
10. Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.
Zlobec I; Bächli M; Galuppini F; Berger MD; Dawson HE; Nagtegaal ID; Lugli A
Virchows Arch; 2021 Dec; 479(6):1085-1090. PubMed ID: 33843013
[TBL] [Abstract][Full Text] [Related]
11. CD36-mediated ferroptosis dampens intratumoral CD8
Ma X; Xiao L; Liu L; Ye L; Su P; Bi E; Wang Q; Yang M; Qian J; Yi Q
Cell Metab; 2021 May; 33(5):1001-1012.e5. PubMed ID: 33691090
[TBL] [Abstract][Full Text] [Related]
12. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tumour budding assessed in gastric carcinoma according to the criteria of the International Tumour Budding Consensus Conference.
Ulase D; Heckl S; Behrens HM; Krüger S; Röcken C
Histopathology; 2020 Feb; 76(3):433-446. PubMed ID: 31538348
[TBL] [Abstract][Full Text] [Related]
14. Histological assessment of stromal maturity as a prognostic factor in surgically treated gastric adenocarcinoma.
Kemi NA; Eskuri M; Pohjanen VM; Karttunen TJ; Kauppila JH
Histopathology; 2019 Dec; 75(6):882-889. PubMed ID: 31173384
[TBL] [Abstract][Full Text] [Related]
15. Tumour-stroma ratio and prognosis in gastric adenocarcinoma.
Kemi N; Eskuri M; Herva A; Leppänen J; Huhta H; Helminen O; Saarnio J; Karttunen TJ; Kauppila JH
Br J Cancer; 2018 Aug; 119(4):435-439. PubMed ID: 30057407
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.
Lugli A; Kirsch R; Ajioka Y; Bosman F; Cathomas G; Dawson H; El Zimaity H; Fléjou JF; Hansen TP; Hartmann A; Kakar S; Langner C; Nagtegaal I; Puppa G; Riddell R; Ristimäki A; Sheahan K; Smyrk T; Sugihara K; Terris B; Ueno H; Vieth M; Zlobec I; Quirke P
Mod Pathol; 2017 Sep; 30(9):1299-1311. PubMed ID: 28548122
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations.
Böger C; Krüger S; Behrens HM; Bock S; Haag J; Kalthoff H; Röcken C
Ann Oncol; 2017 May; 28(5):1005-1014. PubMed ID: 28453696
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
